These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 22235766)
1. Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases. O'Connell K; Thomson M Vet Comp Oncol; 2013 Mar; 11(1):51-62. PubMed ID: 22235766 [TBL] [Abstract][Full Text] [Related]
2. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048 [TBL] [Abstract][Full Text] [Related]
3. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. Kiupel M; Webster JD; Miller RA; Kaneene JB J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175 [TBL] [Abstract][Full Text] [Related]
5. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436 [TBL] [Abstract][Full Text] [Related]
6. Comparison of mitotic index and Ki67 index in the prognostication of canine cutaneous mast cell tumours. Berlato D; Murphy S; Monti P; Stewart J; Newton JR; Flindall A; Maglennon GA Vet Comp Oncol; 2015 Jun; 13(2):143-50. PubMed ID: 23489679 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187 [TBL] [Abstract][Full Text] [Related]
8. Canine subcutaneous mast cell tumor: characterization and prognostic indices. Thompson JJ; Pearl DL; Yager JA; Best SJ; Coomber BL; Foster RA Vet Pathol; 2011 Jan; 48(1):156-68. PubMed ID: 21078881 [TBL] [Abstract][Full Text] [Related]
9. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Cooper M; Tsai X; Bennett P Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648 [TBL] [Abstract][Full Text] [Related]
10. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Welle MM; Bley CR; Howard J; Rüfenacht S Vet Dermatol; 2008 Dec; 19(6):321-39. PubMed ID: 18980632 [TBL] [Abstract][Full Text] [Related]
11. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327 [TBL] [Abstract][Full Text] [Related]
12. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). Stefanello D; Buracco P; Sabattini S; Finotello R; Giudice C; Grieco V; Iussich S; Tursi M; Scase T; Di Palma S; Bettini G; Ferrari R; Martano M; Gattino F; Marrington M; Mazzola M; Elisabetta Vasconi M; Annoni M; Marconato L J Am Vet Med Assoc; 2015 Apr; 246(7):765-9. PubMed ID: 25794126 [TBL] [Abstract][Full Text] [Related]
13. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. Stanclift RM; Gilson SD J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109 [TBL] [Abstract][Full Text] [Related]
16. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. Taylor F; Gear R; Hoather T; Dobson J J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421 [TBL] [Abstract][Full Text] [Related]
17. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. Kodre V; Cemazar M; Pecar J; Sersa G; Cor A; Tozon N In Vivo; 2009; 23(1):55-62. PubMed ID: 19368125 [TBL] [Abstract][Full Text] [Related]
18. Cytologic comparison of the percentage of mast cells in lymph node aspirate samples from clinically normal dogs versus dogs with allergic dermatologic disease and dogs with cutaneous mast cell tumors. Mutz ML; Boudreaux BB; Royal A; Merchant S; Pucheu-Haston C; Griffith EH; Gieger TL J Am Vet Med Assoc; 2017 Aug; 251(4):421-428. PubMed ID: 28763275 [TBL] [Abstract][Full Text] [Related]
19. Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours. Preziosi R; Sarli G; Paltrinieri M Vet Res Commun; 2007 Apr; 31(3):287-96. PubMed ID: 17195927 [TBL] [Abstract][Full Text] [Related]
20. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Malone EK; Rassnick KM; Wakshlag JJ; Russell DS; Al-Sarraf R; Ruslander DM; Johnson CS; Trump DL Vet Comp Oncol; 2010 Sep; 8(3):209-20. PubMed ID: 20691028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]